Active hepatitis B or hepatitis C infectionXx_NEWLINE_xXParticipants with active hepatitis B or hepatitis CXx_NEWLINE_xXKnown active viral or nonviral hepatitis or cirrhosisXx_NEWLINE_xXPatients with untreated or active hepatitis B or C infectionXx_NEWLINE_xXActive hepatitis B or hepatitis C with abnormal liver function testsXx_NEWLINE_xXPatients with known hepatitis B or hepatitis C are not eligible, regardless of concomitant antiretroviral therapy or current viral loadXx_NEWLINE_xXPatients with known active hepatitis B or CXx_NEWLINE_xXNo known chronic active liver disease or evidence of acute or chronic hepatitis B virus (HBV) or hepatitis C (HCV)Xx_NEWLINE_xXRecent history of hepatitis infection or if the treating physician determined that the patient would be at significant risk of reactivation of hepatitisXx_NEWLINE_xXPatients with known active hepatitis (i.e. hepatitis B or C)Xx_NEWLINE_xXLiver disease including history of viral hepatitis B or C, evidence of cirrhosis, chronic active or persistent hepatitisXx_NEWLINE_xXKnown history of hepatitis C infection or suspected currently active hepatitis C infection; known or suspected history of hepatitis B infection will be excluded when any of the following conditions are met:\r\n* Received hematopoietic stem cell transplantation (either allogenic or autologous), or\r\n* Received any rituximab-containing treatment regimen in the last 12 months before entering the study, or\r\n* Active hepatitis B as deemed by serology or viral loadXx_NEWLINE_xXPositive hepatitis C serology or active hepatitis B infection; chronic asymptomatic viral hepatitis is allowedXx_NEWLINE_xXPatients with known active hepatitis B or C; baseline testing is not requiredXx_NEWLINE_xXActive hepatitis B or hepatitis CXx_NEWLINE_xXMust have Child-Pugh A only. Participants may have any viral status (hepatitis B, hepatitis C, or none).Xx_NEWLINE_xXPatients with clinically active hepatitis A, B, or C infections are not eligible\r\n* Note: patients with a history of hepatitis may be eligible if they have a normal titer; such cases should be approved by the study principal investigator (PI)Xx_NEWLINE_xXPatients with a known history of infection with hepatitis B or hepatitis C virus (active, previously treated, or both) will not be eligible due to the increased risk of hepatotoxicity and viral reactivation associated with systemic chemotherapyXx_NEWLINE_xXPatients must not have a history of chronic or active hepatitis B or C infection; patients must have negative hepatitis B and C serologies performed within 28 days prior to registrationXx_NEWLINE_xXActive hepatitis B infectionXx_NEWLINE_xXActive hepatitis C infectionXx_NEWLINE_xXSubject with seropositivity for hepatitis B or hepatitis C must be cleared by hepatology service prior to participating in treatment protocolXx_NEWLINE_xXActive hepatitis A, B, or C infection.Xx_NEWLINE_xXHas a known history of Hepatitis B or known active Hepatitis C virus infection.Xx_NEWLINE_xXPositive for Hepatitis C or Chronic Hepatitis C.Xx_NEWLINE_xXActive or chronic viral hepatitis B or C infectionXx_NEWLINE_xXActive hepatitis B viral infection (defined as HBsAg+).Xx_NEWLINE_xXParticipants with active chronic or acute hepatitis C or B infectionXx_NEWLINE_xXKnown infection with HIV, hepatitis B, or hepatitis CXx_NEWLINE_xXActive or chronic hepatitis B or hepatitis C.Xx_NEWLINE_xXKnown active or chronic hepatitis B or C infection or HIVXx_NEWLINE_xXPatients who have HIV, Hepatitis B or CXx_NEWLINE_xXHas a known history of hepatitis B and/or hepatitis C infectionXx_NEWLINE_xXActive hepatitis B or C or a history of HIV infectionXx_NEWLINE_xXPatient has known active hepatitis B infection (defined as presence of hepatitis B surface antigen [HepB sAg] and/ or hepatitis B [Hep B] deoxyribonucleic acid [DNA]), active hepatitis C infection (defined as presence of Hep C RNA) and/or known human immunodeficiency virus (HIV); patients with HIV who have a normal CD4 count (>= 200) and an undetectable viral load are not excludedXx_NEWLINE_xXActive or chronic hepatitis B or C infection\r\n* Previously infected with evidence of immunity and no evidence of active hepatitis is not an exclusion criterionXx_NEWLINE_xXKnown active hepatitis B and/or CXx_NEWLINE_xXPatients with known hepatitis B or C; screening for hepatitis B and/or C is not required for eligibility for this studyXx_NEWLINE_xXPatients with cirrhosis, or active viral or nonviral hepatitisXx_NEWLINE_xXChronic or active hepatitis B or C, requiring antiviral therapyXx_NEWLINE_xXKnown active hepatitis A, B or CXx_NEWLINE_xXActive hepatitis B and/or hepatitis C infectionXx_NEWLINE_xXKnown immunodeficiency or HIV, Hepatitis B, or Hepatitis C positivity. Antibody to Hepatitis B or C without evidence of active infection may be allowed.Xx_NEWLINE_xXActive hepatitis B or hepatitis CXx_NEWLINE_xXPositive serology for hepatitis B or hepatitis C or known HIV infectionXx_NEWLINE_xXKnown history of HIV, hepatitis C or hepatitis B infectionXx_NEWLINE_xXKnown history of HIV, hepatitis B, or hepatitis C infectionXx_NEWLINE_xXActive Hepatitis B or C infectionXx_NEWLINE_xXPrior to start of everolimus, the following three categories of patients should be tested for hepatitis B viral load and serologic markers, that is, HBV-DNA, HBsAg, hepatitis B surface (HBs) antibody (Ab), and hepatitis B core (HBc) Ab\r\n* All patients who currently live in (or have lived in) Asia, Africa, Central and South America, Eastern Europe, Spain, Portugal and Greece\r\n* Patients with any of the following risk factors:\r\n** Known or suspected past hepatitis B infection,\r\n** Blood transfusion(s) prior to 1990,\r\n** Current or prior intravenous (IV) drug users,\r\n** Current or prior dialysis,\r\n** Household contact with hepatitis B infected patient(s),\r\n** Current or prior high-risk sexual activity,\r\n** Body piercing or tattoos,\r\n** Mother known to have hepatitis B\r\n** History suggestive of hepatitis B infection, e.g., dark urine, jaundice, right upper quadrant pain\r\n** Additional patients at the discretion of the investigatorXx_NEWLINE_xXHepatitis B or CXx_NEWLINE_xXHistory of Hepatitis B, C, or HIVXx_NEWLINE_xXKnown active hepatitis B or CXx_NEWLINE_xXActive hepatitis A, B, or C infectionXx_NEWLINE_xXLiver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitisXx_NEWLINE_xXHistory of hepatitis BXx_NEWLINE_xXA history of active hepatitis B and/or hepatitis C infectionXx_NEWLINE_xXPatients who have known active hepatitis B or CXx_NEWLINE_xXParticipants with known active or chronic infection with hepatitis B or C.Xx_NEWLINE_xXHas a known history of Hepatitis B or Hepatitis C.Xx_NEWLINE_xXParticipants with known positive test for hepatitis B or C indicating acute or chronic infectionXx_NEWLINE_xXKnown to be positive for HIV or hepatitis B, or known to have active hepatitis C infectionXx_NEWLINE_xXHas known active Hepatitis B or known active Hepatitis C virus infection.Xx_NEWLINE_xXParticipant has known infection with hepatitis B or hepatitis C.Xx_NEWLINE_xXKnown active hepatic disease (ie, Hepatitis B or C)Xx_NEWLINE_xXKnown active Hepatitis B or Hepatitis CXx_NEWLINE_xXParticipants with known active hepatitis B or hepatitis CXx_NEWLINE_xXHas a known history of hepatitis B or known active hepatitis C virus infectionXx_NEWLINE_xXActive hepatitis B and hepatitis C virus infectionXx_NEWLINE_xXENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Patients with known active hepatitis B and/or active hepatitis C infectionXx_NEWLINE_xXPatients with known active Hepatitis B or Hepatitis C infectionXx_NEWLINE_xXParticipants with known acute or chronic hepatitis B or hepatitis CXx_NEWLINE_xXParticipants with known active hepatitis B or CXx_NEWLINE_xXKnown active HIV, hepatitis B or hepatitis C, where active is defined as follows:Xx_NEWLINE_xXPatient with active Hepatitis B or C determined by serology and/or NAAT.Xx_NEWLINE_xXKnown active Hepatitis B or CXx_NEWLINE_xXHepatitis B or CXx_NEWLINE_xXKnown hepatitis B surface antigen-positive or known or suspected active hepatitis C infection.Xx_NEWLINE_xXActive hepatitis B or C (testing required).Xx_NEWLINE_xXKnown active hepatitis B or C or known infection with HIVXx_NEWLINE_xXActive hepatitis B or hepatitis CXx_NEWLINE_xXPatients with history of hepatitis B and hepatitis C will be eligible but patients with hepatitis B must be started on antiviral therapy prior to beginning study therapyXx_NEWLINE_xXHas known active Hepatitis B or C. Active Hepatitis B.Xx_NEWLINE_xXPatient has known active hepatitis B infection (defined as presence of hepatitis B [HepB] surface antigen [sAg] and/or Hep B deoxyribonucleic acid [DNA]), active hepatitis C infection (defined as presence of hepatitis C [Hep C] ribonucleic acid [RNA]) and/or known human immunodeficiency virus (HIV) carrier (HIV 1/2 antibodies)Xx_NEWLINE_xXKnown history of active tuberculosis (TB), autoimmune disease, pneumonitis, infection, HIV, Hepatitis B, or Hepatitis CXx_NEWLINE_xXKnown active hepatitis B or hepatitis CXx_NEWLINE_xXKnown history of active tuberculosis (TB), autoimmune disease, pneumonitis, infection, HIV, Hepatitis B, or Hepatitis CXx_NEWLINE_xXKnown hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infectionXx_NEWLINE_xXPositive for Hepatitis C or chronic Hepatitis CXx_NEWLINE_xXKnown active hepatitis B infection (defined as presence of hepatitis B [HepB] surface antigen [sAg] and/or Hep B deoxyribonucleic acid [DNA]), known active hepatitis C infection (defined as presence of hepatitis C [Hep C] ribonucleic acid [RNA]) and/or known human immunodeficiency virus (HIV) carrierXx_NEWLINE_xXChronic active Hepatitis B or C.Xx_NEWLINE_xXHistory of chronic hepatitis B or CXx_NEWLINE_xXPatients with known active Hepatitis C, HIV or a present history of Hepatitis BXx_NEWLINE_xXActive hepatitis B (HBV) or hepatitis C (HCV) infectionXx_NEWLINE_xXActive hepatitis A, hepatitis B, or hepatitis C infectionXx_NEWLINE_xXKnown active hepatitis A, B, or CXx_NEWLINE_xXPatients with active hepatitis A, hepatitis B, or hepatitis C infectionXx_NEWLINE_xXPatients with cirrhosis, or active viral or nonviral hepatitisXx_NEWLINE_xXKnown hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infectionXx_NEWLINE_xXActive hepatitis B or C infectionXx_NEWLINE_xXHepatitis B or HIV infectionXx_NEWLINE_xXPatients with hepatitis B infection must be on appropriate antiviral therapyXx_NEWLINE_xXActive hepatitis B or C infectionXx_NEWLINE_xXKnown active hepatitis B or CXx_NEWLINE_xXDONOR: With active infectious hepatitisXx_NEWLINE_xXPatients with known active hepatitis (i.e. hepatitis B or C) due to risk of transmitting the infection through blood or other body fluidsXx_NEWLINE_xXHas evidence of acute or chronic hepatitis B or hepatitis CXx_NEWLINE_xXKnown diagnosis of active hepatitis B or hepatitis CXx_NEWLINE_xXSubject has a diagnosis of chronic active hepatitis B or C.Xx_NEWLINE_xXActive hepatitis B or active hepatitis C;Xx_NEWLINE_xXActive hepatitis B, hepatitis C at the time of screeningXx_NEWLINE_xXKnown hepatitis B or hepatitis C infectionXx_NEWLINE_xXEvidence of active Hepatitis B, active Hepatitis C infection (HCV) or cytomegalovirus (CMV) or known history of HIV.Xx_NEWLINE_xXPatients with active viral hepatitis.Xx_NEWLINE_xXSubjects with known active hepatitis (i.e. hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids.Xx_NEWLINE_xXActive infections including hepatitis B carrier status, hepatitis C virus (HCV) infection (patients must have a negative hepatitis [hep] B and hep C viral load at screening)Xx_NEWLINE_xXKnown hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection.Xx_NEWLINE_xXHas a known history of Hepatitis B or known active Hepatitis C virus infectionXx_NEWLINE_xXKnown history of hepatitis B or hepatitis C infection or known positive test for hepatitis B surface antigen, hepatitis B core antigen, or hepatitis C polymerase chain reactionXx_NEWLINE_xXActive hepatitis B or C infectionXx_NEWLINE_xXCOHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Patients who have known active hepatitis B, or hepatitis C infectionsXx_NEWLINE_xXCOHORT 2: TRIPLE NEGATIVE BREAST CANCER: Patients who have known active hepatitis B, or hepatitis C infectionsXx_NEWLINE_xXCOHORT 3: ENDOMETRIAL CANCER: Patients who have known active hepatitis B, or hepatitis C infectionXx_NEWLINE_xXChronic, active, or acute viral hepatitis A, B, or C infection, or hepatitis B or C carrierXx_NEWLINE_xXPatients with known active human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection; patients with a history of hepatitis B or hepatitis C, who are deemed cured and no longer require treatment may be allowed to enroll after consultation with the respective specialist and the study PIXx_NEWLINE_xXActive Hepatitis C infection. Subjects who have been treated for Hepatitis C infection can be included if they have documented sustained virologic response of ? 12 weeks.Xx_NEWLINE_xXActive or chronic viral hepatitis B or C infection Exclusions Related to Ocular DiseaseXx_NEWLINE_xXHas known active hepatitis B or hepatitis C virus infection.Xx_NEWLINE_xXActive ongoing infection requiring therapy; patients with known chronic hepatitis C infection will be allowed if antiviral therapy is not in use; patients with evidence of chronic hepatitis B infection as evidenced by hepatitis B surface antigen positivity and/or evidence of hepatitis B circulating deoxyribonucleic acid (DNA) are required to receive viral prophylaxis while on treatment with entecavir or tenofavir per institutional guidelines; hepatitis viral load studies will be followed as described in protocolXx_NEWLINE_xXKnown history of HIV or active hepatitis B/C (patients who have been vaccinated for hepatitis B and do not have a history of infection are eligible)Xx_NEWLINE_xXActive hepatitis B, hepatitis C at the time of screeningXx_NEWLINE_xXNo active hepatitis or diagnosis of HIV disease.Xx_NEWLINE_xXKnown active hepatitis infectionXx_NEWLINE_xXActive liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitisXx_NEWLINE_xXSubject has active infectious hepatitis, type A, B, or C, or chronic carriers of hepatitis C.Xx_NEWLINE_xXSubjects with known HIV or active viral hepatitisXx_NEWLINE_xXKnown active hepatitis B or CXx_NEWLINE_xXKnown hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infectionXx_NEWLINE_xXActive infection including hepatitis B-carrier status, hepatitis C virus (HCV) infection (patients must have a negative hepatitis [Hep] B and Hep C viral load at screening)Xx_NEWLINE_xXKnown active viral or nonviral hepatitis or cirrhosisXx_NEWLINE_xXActive hepatitis A, hepatitis B, or hepatitis C infectionXx_NEWLINE_xXActive hepatitis B or hepatitis C infectionXx_NEWLINE_xXActive hepatitis B infection as documented by positive hepatitis B polymerase chain reaction (PCR) assayXx_NEWLINE_xXActive hepatitis B. Patients with chronic hepatitis B who are on appropriate viral suppressive therapy may be allowed after discussion with the principal investigator (PI).Xx_NEWLINE_xXAny known positive test for hepatitis B or hepatitis C virus indicating acute or chronic infection is not permittedXx_NEWLINE_xXKnown positivity for hepatitis B or CXx_NEWLINE_xXHas an active bacterial, fungal, and/or known viral infection; patients with known human immunodeficiency virus (HIV) infection are excluded given the potential for interactions between antiretroviral agents and abemaciclib, and the potential for increased risk of life threatening infection with therapy that is myelosuppressive; patients with known hepatitis B or hepatitis C infection are excluded only if there is evidence of active infection (detectable hepatitis B surface antigen, detectable hepatitis C ribonucleic acid [RNA])Xx_NEWLINE_xXPatients who are carriers of hepatitis virus B and C; hepatitis B and C testing must be performed to confirm status prior to enrollmentXx_NEWLINE_xXHistory of hepatitis B or C or chronic hepatitisXx_NEWLINE_xXKnown to be positive for HIV, Hepatitis B, or Hepatitis CXx_NEWLINE_xXKnown HIV, Hepatitis A, B or C infection.Xx_NEWLINE_xXActive hepatitis B or C infectionXx_NEWLINE_xXKnown hepatitis B or hepatitis C with abnormal liver function testsXx_NEWLINE_xXPatients with positive hepatitis serology that is definitive of active disease.Xx_NEWLINE_xXPatients with chronic active hepatitis or cirrhosis. If positive hepatitis serology, the study chair may deem the patient eligible based on the results of liver biopsy.Xx_NEWLINE_xXActive hepatitis A, B or C infectionXx_NEWLINE_xXClinically active infection with hepatitis B or hepatitis C virusXx_NEWLINE_xXActive infection with hepatitis B; active or chronic infection with hepatitis CXx_NEWLINE_xXPatient has known active hepatitis B infection (defined as presence of hepatitis B [HepB] surface antigen (sAg) and/ or Hep B deoxyribonucleic acid [DNA]), active hepatitis C infection (defined as presence of hepatitis C [Hep C] ribonucleic acid [RNA]) and/or known human immunodeficiency virus (HIV) carrier (HIV 1/2 antibodies)Xx_NEWLINE_xXPrior or ongoing liver disease including known cirrhosis, active hepatitis B or C infection; not to exclude patients with a distant history of resolved hepatitis A infectionXx_NEWLINE_xXPatients with a known history of hepatitis B or hepatitis CXx_NEWLINE_xXKnown active hepatitis (i.e. hepatitis B or C) due to risk of transmitting the infection through blood or other body fluidsXx_NEWLINE_xXKnown history of chronic hepatitis B or CXx_NEWLINE_xXPatients with known active hepatitis (i.e. Hepatitis B or C)Xx_NEWLINE_xXPositive test results for chronic hepatitis B and hepatitis C infectionXx_NEWLINE_xXAll participants will be required to be screened for hepatitis C; if hepatitis C antibody positive, with or without a positive hepatitis C RNA level, participants will be permitted to enroll in the study provided liver function tests meet criteria listed, and have no evidence of cirrhosis; participants diagnosed with hepatitis C less than 6 months from trial enrollment will be considered to have acute hepatitis C, and will be excluded from study UNLESS hepatitis C viral load is undetectableXx_NEWLINE_xXBe undergoing treatment for acute or chronic hepatitis C.Xx_NEWLINE_xXKnown human immunodeficiency virus or hepatitis C infection only if the patient is taking medications that are excluded per protocol, active hepatitis B, or active hepatitis C infection.Xx_NEWLINE_xXPatients with known active hepatitis B or hepatitis CXx_NEWLINE_xXChronic active or active viral hepatitis A, B, or C infectionXx_NEWLINE_xXKnown hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection.Xx_NEWLINE_xXEvidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serologyXx_NEWLINE_xXOn treatment for hepatitis B or hepatitis C or history of tuberculosis (TB)Xx_NEWLINE_xXKnown hepatitis B surface antigen-positive, or known or suspected active hepatitis C infectionXx_NEWLINE_xXActive tuberculosis or hepatitis, or history of hepatitis B or C, or chronic hepatitisXx_NEWLINE_xXKnown hepatitis B or hepatitis C infection; EXCEPTION: if viral load < 800,000 IU/LXx_NEWLINE_xXKnown hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infectionXx_NEWLINE_xXActive hepatitis B or C infectionXx_NEWLINE_xXKnown active viral hepatitis, HIV or chronic liver disease.Xx_NEWLINE_xXKnown active infection with HIV, hepatitis B, hepatitis CXx_NEWLINE_xXPatients known to be HIV positive or have active viral hepatitis.Xx_NEWLINE_xXKnown hepatitis B surface antigen-positive, or known or suspected active hepatitis C infectionXx_NEWLINE_xXSubjects must not have a history of any positive test for hepatitis B or hepatitis C indicating active disease or previous exposureXx_NEWLINE_xXHas a known active hepatitis B or hepatitis C.Xx_NEWLINE_xXActive hepatitis B or C infectionXx_NEWLINE_xXKnown active hepatitis B or CXx_NEWLINE_xXHas a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient’s participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator; this includes known active tuberculosis; grade 3 active infection; history of allogeneic bone marrow transplant or solid organ transplant; known history of human immunodeficiency virus (HIV); known active hepatitis B (eg, hepatitis [Hep] B deoxyribonucleic acid [DNA] positive in prior 3 months) or known active hepatitis C (eg, hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected in prior 3 months)Xx_NEWLINE_xXPatients cannot have previously been treated with interferons (e.g., for chronic active hepatitis)Xx_NEWLINE_xXHepatitis C on protease therapyXx_NEWLINE_xXKnown history of hepatitis C or known active hepatitis B infectionXx_NEWLINE_xXActive hepatitis B or hepatitis C treatmentXx_NEWLINE_xXNo active infection with Hepatitis B.Xx_NEWLINE_xXNo active infection with Hepatitis C.Xx_NEWLINE_xXKnown hepatitis B or C infectionXx_NEWLINE_xXHas known hepatitis B or hepatitis CXx_NEWLINE_xXKnown or chronic hepatitis C and/or B infectionXx_NEWLINE_xXAny known positive test for hepatitis B or hepatitis C virus indicating acute or chronic infection is not permittedXx_NEWLINE_xXPatients with active hepatitis A, hepatitis B, or hepatitis C infectionXx_NEWLINE_xXPatients with active hepatitis B and CXx_NEWLINE_xXPre-existing viral hepatitisXx_NEWLINE_xXPatients with known active hepatitis B, or hepatitis C will be excludedXx_NEWLINE_xXActive, uncontrolled infection including known hepatitis B or CXx_NEWLINE_xXKnown or suspected active hepatitis B or C infectionXx_NEWLINE_xXChronic infection with hepatitis B or hepatitis C virusXx_NEWLINE_xXRuxolitinib\r\n* Chronic active hepatitis C (HCV)Xx_NEWLINE_xXActive or chronic hepatitis B infectionXx_NEWLINE_xXKnown hepatitis B surface antigen-positive, or known or suspected active hepatitis C infectionXx_NEWLINE_xXKnown hepatitis B surface antigen-positive, or known or suspected active hepatitis\r\nC infectionXx_NEWLINE_xXKnown active hepatitis B or C infection, or HIV infection.Xx_NEWLINE_xXHistory of chronic hepatitis B or CXx_NEWLINE_xXHas active hepatitis B or C. Patients with serologic evidence of prior exposure are eligible.Xx_NEWLINE_xXActive infection with hepatitis B or hepatitis C virusXx_NEWLINE_xXPatients with a known history of hepatitis B or hepatitis C are not eligibleXx_NEWLINE_xXPatients with active B or C hepatitis.Xx_NEWLINE_xXPatients who have active infectious hepatitisXx_NEWLINE_xXHistory of renal or hepatic disease, including history of hepatitis B or CXx_NEWLINE_xXActive hepatitis B or hepatitis C infectionXx_NEWLINE_xXActive HIV or hepatitis B or C infectionXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); known hepatitis C infection is allowed as long as there is no active disease and is cleared by gastrointestinal (GI) consultationXx_NEWLINE_xXKnown active hepatitis B or CXx_NEWLINE_xXActive hepatitis, including but not limited to viral and drug-inducedXx_NEWLINE_xXChronic or active hepatitis B or C infection requiring treatment with antiviral therapyXx_NEWLINE_xXActive hepatitis B or hepatitis C infectionXx_NEWLINE_xXKnown hepatitis B surface antigen-positive, or known or suspected active hepatitis C infectionXx_NEWLINE_xXEvidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serologyXx_NEWLINE_xXActive hepatitis B or active hepatitis CXx_NEWLINE_xXKnown history of HIV disease, active hepatitis B or hepatitis C.Xx_NEWLINE_xXParticipants with active hepatitis A, B or C infection.Xx_NEWLINE_xXKnown active hepatitis B and/or hepatitis C infectionXx_NEWLINE_xXKnown active viral or other chronic types hepatitides (hepatitis B, C) or cirrhosisXx_NEWLINE_xXActive hepatitis B or active hepatitis CXx_NEWLINE_xXKnown history of Hepatitis B or C or HIVXx_NEWLINE_xXEvidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serologyXx_NEWLINE_xXPatients tested positive for hepatitis B or with a known, active hepatitis C infectionXx_NEWLINE_xXKnown active Hepatitis B or C infectionXx_NEWLINE_xXEvidence of active infection by hepatitis B and/or C; for patients with hepatitis B treated with anti-virals to undetectable viral load, and for patients with hepatitis C with undetectable ribonucleic acid (RNA) levels and no evidence of liver damage, enrollment may be considered and should discuss first with study’s principal investigatorXx_NEWLINE_xXSubjects with known active acute hepatitisXx_NEWLINE_xXPatients with a known history of hepatitis B or CXx_NEWLINE_xXNegative for hepatitis A, B, or C infectionXx_NEWLINE_xXEvidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serologyXx_NEWLINE_xXPatients with hepatitis B infection must be on appropriate antiviral therapyXx_NEWLINE_xXChronic or active hepatitis B or C infection requiring treatment with antiviral therapyXx_NEWLINE_xXKnown active viral or nonviral hepatitis or cirrhosisXx_NEWLINE_xXPatients with active hepatitis B or C infection (not including patients with prior hepatitis B vaccination); these patients should be cleared by gastrointestinal (GI) consultation for hepatitis B and infectious disease consult for hepatitis CXx_NEWLINE_xXKnown active hepatitis B virus hepatitis, or known active hepatitis C virusXx_NEWLINE_xXHas a known active hepatitis B or hepatitis CXx_NEWLINE_xXChronic hepatitis infection, including B and CXx_NEWLINE_xXHas uncontrolled HIV or hepatitis B or CXx_NEWLINE_xXPatients with a positive history of hepatitis B or hepatitis CXx_NEWLINE_xXActive hepatitis B or C viral infection or hepatitis B surface antigen positiveXx_NEWLINE_xXNo evidence of chronic active hepatitis or cirrhosisXx_NEWLINE_xXKnown hepatitis B surface antigen-positive, known or suspected active hepatitis C infection (testing not required).Xx_NEWLINE_xXKnown active or chronic hepatitis B or C infectionXx_NEWLINE_xXPatients with history of active hepatitis B or C infection or chronic hepatitis with Child Pugh B or C hepatic dysfunctionXx_NEWLINE_xXActive hepatitis B or hepatitis C with abnormal liver function tests; HIV positive patients receiving antivirals.Xx_NEWLINE_xXBaseline hepatitis titers without evidence of acute/active hepatitisXx_NEWLINE_xXActive hepatitisXx_NEWLINE_xXPatients with known history of hepatitis B surface antigen-positive, or known history or suspected active hepatitis C infection are not to be enrolled in the studyXx_NEWLINE_xXPresence of any other active or suspected acute or chronic uncontrolled infection or known symptomatic active hepatitis B or CXx_NEWLINE_xXPatients with hepatitis B and/or hepatitis C infection are excluded if they are on any of the following viral suppressive agents: boceprevir (Victrelis), ribavirin (Rebetol, Ribatab, Ribasphere), telaprevir (Incivek)\r\n* Note: patients with active hepatitis B infection must be on treatment with viral suppressive therapies; these agents may include the following: adefovir (Hepsera), entecavir (Baraclude), lamivudine (Epivir-HBV), telbivudine (Tyzeka), and/or tenofovir (Viread)Xx_NEWLINE_xXSerologic or clinical evidence of current active hepatitis B or C infection, defined as elevated levels of hepatitis (Hep) B antigen or Hep C antibody (unless active infection is ruled out by nucleic acid tests)Xx_NEWLINE_xXAcute or chronic hepatitis B or C infectionXx_NEWLINE_xXPatients with active hepatitis B and/or hepatitis C infectionXx_NEWLINE_xXEvidence of acute or chronic active hepatitis or cirrhosisXx_NEWLINE_xXHistory of chronic hepatitis B or CXx_NEWLINE_xXPatients with known hepatitis or unstable liver disease, and/or positive serologies for Hepatitis B or C and HIV.Xx_NEWLINE_xXUncontrolled active hepatitis B or active hepatitis CXx_NEWLINE_xXActive hepatitis B or hepatitis C infectionXx_NEWLINE_xXKnown active hepatitis B or C infectionXx_NEWLINE_xXAny history of hepatitis B infectionXx_NEWLINE_xXPatient with known active infection with HIV, hepatitis B or hepatitis CXx_NEWLINE_xXHistory of chronic or active hepatitisXx_NEWLINE_xXKnown HIV positive or active hepatitis B or CXx_NEWLINE_xXMust not have known active or clinically significant hepatitis A, B or C infection.Xx_NEWLINE_xXPatients with cirrhosis, or active viral or non-viral hepatitisXx_NEWLINE_xXPatients with a known confirmed diagnosis of HIV infection or active viral hepatitis.Xx_NEWLINE_xXPresence of an active acute or chronic infection including: a urinary tract infection as determined by their physician, HIV (as determined by enzyme-linked immunosorbent assay [ELISA] and confirmed by Western blot) or viral hepatitis (as determined by hepatitis B surface antigen [HBsAg] and hepatitis C serology)Xx_NEWLINE_xXRelapsed/refractory MCL: Known human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); known hepatitis C infection is allowed as long as there is no active disease and is cleared by gastrointestinal (GI) consultationXx_NEWLINE_xXNewly diagnosed MCL: Known HIV infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum Hepatitis B antibody); known hepatitis C infection is allowed as long as there is no active disease and is cleared by GI consultationXx_NEWLINE_xXNo evidence of chronic active hepatitis or cirrhosisXx_NEWLINE_xXChronic hepatitis B or hepatitis C infectionXx_NEWLINE_xXPatients with known active hepatitis B or C, or HIV infection.Xx_NEWLINE_xXKnown HIV, Hepatitis B, or Hepatitis C.Xx_NEWLINE_xXEvidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serologyXx_NEWLINE_xXPatient has known history of active hepatitis A, B, or CXx_NEWLINE_xXDONOR: Active infectious hepatitisXx_NEWLINE_xXActive hepatitis B or C viral infection or hepatitis B surface antigen positiveXx_NEWLINE_xXPatients with active hepatitis B and/or hepatitis C infectionXx_NEWLINE_xXActive hepatitis B or C infectionXx_NEWLINE_xXKnown hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infectionXx_NEWLINE_xXKnown positivity for hepatitis B infectionXx_NEWLINE_xXKnown active hepatitis C infectionXx_NEWLINE_xXPatients with active hepatitis are excludedXx_NEWLINE_xXHistory of chronic or active hepatitisXx_NEWLINE_xXHAPLOIDENTICAL DONOR: Chronic active hepatitis B; donor may be hepatitis core antibody positiveXx_NEWLINE_xXHistory of chronic or active hepatitisXx_NEWLINE_xXPatients with a history of hepatitis B with persistent infection.Xx_NEWLINE_xXEvidence of either cirrhosis or stage 3-4 liver fibrosis in patients who either show chronic hepatitis C or positive hepatitis C serologyXx_NEWLINE_xXPatient who has active Hepatitis BXx_NEWLINE_xXKnown Hepatitis B Ag positive, Hepatitis C positive patientsXx_NEWLINE_xXPatient has active hepatitis BXx_NEWLINE_xXHas a prior history of viral hepatitis (B or C) as demonstrated by positive serology (presence of antigens) or have an uncontrolled infection requiring treatment. Participants with a known prior history of hepatitis B or C may be eligible pending agreement with the sponsor.Xx_NEWLINE_xXChronic or active hepatitis B or C if not controlled by antiviral therapyXx_NEWLINE_xXActive infection requiring systemic therapy, known infection of HIV, Hepatitis B, or Hepatitis C.Xx_NEWLINE_xXPositive hepatitis C serology or active hepatitis B infectionXx_NEWLINE_xXKnown HIV infection or active Hepatitis B or Hepatitis C virus infectionXx_NEWLINE_xXAcute or chronic hepatitis B or hepatitis C.Xx_NEWLINE_xXPatients with known HIV, hepatitis B or C;Xx_NEWLINE_xXPatients with active Hepatitis B infection (HBsAg positive) that are not receiving antiviral treatment are excludedXx_NEWLINE_xXActive hepatitis A or B.Xx_NEWLINE_xXHas known active Hepatitis B or Hepatitis C.Xx_NEWLINE_xXActive hepatitis A or B.Xx_NEWLINE_xXKnown immunodeficiency or HIV, Hepatitis B, or Hepatitis C positivity. Antibody to Hepatitis B or C without evidence of active infection may be allowed.Xx_NEWLINE_xXSubject has known active hepatitis B or hepatitis C infection.Xx_NEWLINE_xXPatients who have a known history of hepatitis C or chronic active hepatitis B or a known diagnosis of HIVXx_NEWLINE_xXActive HIV, hepatitis B or CXx_NEWLINE_xXPatients must not have a history of HIV, or active Hepatitis A, B, and C.Xx_NEWLINE_xXA history of known, active hepatitisXx_NEWLINE_xXPatient is known to be hepatitis B surface antigen-positive or has known active hepatitis C infection.Xx_NEWLINE_xXPatients with chronic active hepatitis or cirrhosis; if positive hepatitis serology, the study chair may deem the patient eligible based on the results of liver biopsyXx_NEWLINE_xXPrior, current, or chronic hepatitis B or hepatitis C infectionXx_NEWLINE_xXActive hepatitis B or C or other active liver disease.Xx_NEWLINE_xXActive hepatitis B or hepatitis C infection at the time of screeningXx_NEWLINE_xXPatients with non-hepatocellular carcinoma must not have acute or chronic hepatitis B or hepatitis C infectionXx_NEWLINE_xXHPV-ASSOCIATED OROPHARYNX SQUAMOUS CELL CARCINOMA: Known infection with hepatitis B, hepatitis C, or HIVXx_NEWLINE_xXPatients with known active hepatitis (i.e., hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids.Xx_NEWLINE_xXPatients with known active hepatitis (i.e., hepatitis B or C) due to risk of transmitting the infection through blood or other body fluidsXx_NEWLINE_xXKnown history of Hepatitis B or known active Hepatitis C virus.Xx_NEWLINE_xXKnown HIV or chronic Hepatitis B or C infection.Xx_NEWLINE_xXSerologic status reflecting active hepatitis B or C infection.Xx_NEWLINE_xXActive viral hepatitis infection. Subjects with history of hepatitis infection that is not active are eligible.Xx_NEWLINE_xXPatients known to be have active hepatitis B or C; (hepatitis B positive patients are allowed if they are on appropriate antiviral agents such as lamivudine)Xx_NEWLINE_xXActive hepatitis B or hepatitis C infectionXx_NEWLINE_xXEvidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serologyXx_NEWLINE_xXActive hepatitis B or active hepatitis C.Xx_NEWLINE_xXPatients with known active or history of chronic hepatitis C and/or B infection, and active alcohol or drug abuse are not eligibleXx_NEWLINE_xXKnown acute viral hepatitisXx_NEWLINE_xXActive hepatitis B or C infectionXx_NEWLINE_xXKnown hepatitis (hep) B or C, or known cirrhosis (screening for viral hepatitis is not required)Xx_NEWLINE_xXActive viral hepatitis.Xx_NEWLINE_xXEvidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology.Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV) infection. Patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody). Known hepatitis C infection is allowed as long as there is no active disease. These patients should be optimized by GI consultation for hepatitis B and infectious disease consult for hepatitis C.Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV) infection. Patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody). Known hepatitis C infection is allowed as long as there is no active disease and is cleared by GI consultation.Xx_NEWLINE_xXHas known active hepatitis B or hepatitis C infectionXx_NEWLINE_xXActive hepatitis B, hepatitis CXx_NEWLINE_xXSubjects with a history of chronic or acute hepatitis C or B infection.Xx_NEWLINE_xXHistory of chronic hepatitis B or C infectionXx_NEWLINE_xXKnown active or chronic hepatitis B or C infection or HIVXx_NEWLINE_xXBe undergoing treatment for acute or chronic hepatitis C.Xx_NEWLINE_xXKnown active HIV, HBV, or HCV infection. Inactive hepatitis carrier status or low viral hepatitis titer on antivirals is allowed.Xx_NEWLINE_xXKnown active hepatitis B or active hepatitis C infection; participants who have prior hepatitis C infection but who have received an antiviral treatment and show no detectable viral ribonucleic acid (RNA) for 6 months after completion of treatment are eligibleXx_NEWLINE_xXKnown history of or positive test for hepatitis B or hepatitis C infection.Xx_NEWLINE_xXPatients with known acute or chronic hepatitis B or hepatitis C infection are ineligibleXx_NEWLINE_xXChronic or active hepatitis B or C infection requiring treatment with antiviral therapyXx_NEWLINE_xXKnown active hepatitis B or C infection or HIV infection.Xx_NEWLINE_xXPatients with known untreated hepatitis CXx_NEWLINE_xXHistory of chronic hepatitis B or CXx_NEWLINE_xXHepatitis B and C negativeXx_NEWLINE_xXKnown hepatitis B or CXx_NEWLINE_xXPatients with known active hepatitis (i.e. hepatitis B or C)Xx_NEWLINE_xXChronic active untreated hepatitis B or C infectionXx_NEWLINE_xXActive liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitisXx_NEWLINE_xXDONOR: Evidence of active infection or viral hepatitisXx_NEWLINE_xXActive infection including known AIDS or Hepatitis C or with a fever ?38.5°C within 3 days prior to enrollmentXx_NEWLINE_xXSeropositive for any of the following: HIV ab, hepatitis B sAg, hepatitis (hep) C immunoglobulin (Ig)G Ab positive, without definitive therapy for hepatitis C; or hepatitis C PCR positivity; or hepatitis C IgM positivityXx_NEWLINE_xXDONOR: Evidence of active infection or viral hepatitisXx_NEWLINE_xXHistory of chronic hepatitis B or CXx_NEWLINE_xXActive hepatitis B or C infectionXx_NEWLINE_xXPositive hepatitis C serology or active hepatitis B infectionXx_NEWLINE_xXKnown, active hepatitis A, B, or C infectionXx_NEWLINE_xXPatients who have any known history of liver disease, autoimmune hepatitis, sclerosing cholangitis or are found to be carriers (active disease or not) of hepatitis B and hepatitis CXx_NEWLINE_xXActive viral hepatitis or autoimmune hepatitis; the work-up to confirm active hepatitis or autoimmune hepatitis will only be done if clinical suspicion based on investigator discretionXx_NEWLINE_xXChronic hepatitis C based on the judgment of the investigatorXx_NEWLINE_xXCo-infection with hepatitis BXx_NEWLINE_xXPatients with known hepatitis B or hepatitis C (active or carriers)Xx_NEWLINE_xXKnown active hepatitis A, B, or C infection that requires treatmentXx_NEWLINE_xXLiver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitisXx_NEWLINE_xXActive infection with hepatitis B; active or chronic infection with hepatitis CXx_NEWLINE_xXActive hepatitis A, B or C infection\r\n* Hepatitis A serology is not required for normal liver functionXx_NEWLINE_xXChronic hepatitis infection, including B and CXx_NEWLINE_xXActive hepatitis B or hepatitis C with abnormal liver function testsXx_NEWLINE_xXPatients with known hepatitis B or hepatitis C infection must have viral load < 800,000 IU/L within 28 days prior to registrationXx_NEWLINE_xXDONOR: Individuals with active infectious hepatitisXx_NEWLINE_xXKnown positive hepatitis C serology or active hepatitis B infection – chronic asymptomatic viral hepatitis is allowedXx_NEWLINE_xXPatients with hepatitis C antibody will be eligible provided that they do not have elevated liver transaminases or other evidence of active hepatitisXx_NEWLINE_xXChronic hepatitis infection, including B and CXx_NEWLINE_xXKnown Active hepatitis B or CXx_NEWLINE_xXPatients with evidence of hepatitis B or hepatitis C PCR positivityXx_NEWLINE_xXPatients with known active hepatic disease (i.e., hepatitis B or C)Xx_NEWLINE_xXKnown HIV positive or active hepatitis B or C, or presence of hepatitis B surface\n             antigens or presence of hepatitis C antibodyXx_NEWLINE_xXKnown HIV-, hepatitis B-, or hepatitis C-positive patients (active, previously treated, or both)Xx_NEWLINE_xXActive hepatitis including hepatitis B or CXx_NEWLINE_xXActive hepatitis B or C infectionXx_NEWLINE_xXHistory of active hepatitis B or CXx_NEWLINE_xXPatients with liver disease such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitisXx_NEWLINE_xXPatients who have chronic hepatitis B or hepatitis CXx_NEWLINE_xXPatients with active hepatitis B or active hepatitis C infectionXx_NEWLINE_xXPatients with hepatitis BXx_NEWLINE_xXHepatitis C infection; patient may have hepatitis C infection; however, each patient will require a hepatology consultation; the risk/benefit profile of transplant and hepatitis C will be discussed with the patient and eligibility determined by the principal investigator and LAIXx_NEWLINE_xXSubject has active hepatitis B or C, or other active hepatic disorder.Xx_NEWLINE_xXActive systemic hepatitis infection requiring treatment (carriers of hepatitis virus are permitted to enter the study), of any type or known acute or chronic liver disease including cirrhosisXx_NEWLINE_xXKnown HIV, active hepatitis B or active hepatitis C infectionXx_NEWLINE_xXSubject with known active HIV, Hepatitis B, or Hepatitis C infections.Xx_NEWLINE_xXHas known active Hepatitis B or Hepatitis CXx_NEWLINE_xXKnown active Hepatitis B or CXx_NEWLINE_xXActive hepatitis B or C infectionXx_NEWLINE_xXChronic hepatitis (except for subjects with hepatocellular carcinoma)Xx_NEWLINE_xXHas known active hepatitis B or hepatitis C.Xx_NEWLINE_xXHas known history of or is positive for Hepatitis B or Hepatitis CXx_NEWLINE_xXKnown active hepatitis B or hepatitis CXx_NEWLINE_xXActive or latent hepatitis B or active hepatitis C (test within 8 weeks of screening), or any uncontrolled infection at screeningXx_NEWLINE_xXCurrent or active tuberculosis, hepatitis B, or hepatitis C.Xx_NEWLINE_xXKnown to be positive for HIV or known to have active hepatitis B or C.Xx_NEWLINE_xXActive replication of or prior infection with hepatitis B or active hepatitis C( HCV RNA positive )Xx_NEWLINE_xXActive tuberculosis or recent (< 2 week ago) clinically significant infection or evidence of active hepatitis B, hepatitis C or HIV infectionXx_NEWLINE_xXActive hepatitis B or active hepatitis CXx_NEWLINE_xXClinically active infection with hepatitis B or hepatitis C virusXx_NEWLINE_xXHistory of hepatitis (B or C)Xx_NEWLINE_xXKnown history of HIV seropositivity, hepatitis C virus, acute or chronic active hepatitis B infection, or other serious chronic infection requiring ongoing treatmentXx_NEWLINE_xXHIV/active Hepatitis B or C infectionXx_NEWLINE_xXKnown active viral or nonviral hepatitis or cirrhosisXx_NEWLINE_xXActive hepatitis B or C infection based on screening blood testingXx_NEWLINE_xXHas known history of Hepatitis B or known active Hepatitis C.Xx_NEWLINE_xXPatients must not have known HIV, hepatitis B or hepatitis C positivityXx_NEWLINE_xXActive coinfection with both hepatitis B (i.e., HBVsAg and/or hepatitis B DNA) and hepatitis C (i.e., hepatitic C RNA)Xx_NEWLINE_xXHepatitis D infection in subjects with hepatitis BXx_NEWLINE_xXHistory of active or chronic hepatitis (e.g. Hep B or C)Xx_NEWLINE_xXHas known active Hepatitis B or C.Xx_NEWLINE_xXActive or latent hepatitis B or active hepatitis C (test within 8 weeks of screening), or any uncontrolled infection at screeningXx_NEWLINE_xXActive hepatitis B, hepatitis C, or tuberculosisXx_NEWLINE_xXKnown history or evidence of active hepatitis A, B, or C or HIVXx_NEWLINE_xXKnown positive HIV infection, or active hepatitis B or C infectionXx_NEWLINE_xXActive tuberculosis or recent (< 2 week ago) clinically significant infection or evidence of active hepatitis B, hepatitis C or HIV infection.Xx_NEWLINE_xXKnown significant chronic liver disease, such as cirrhosis or active hepatitis (potential participants who test positive for hepatitis B surface antigen or hepatitis C antibodies are allowed provided they do not have active disease requiring antiviral therapy)Xx_NEWLINE_xXBaseline hepatitis tiers without evidence of active hepatitisXx_NEWLINE_xXActive hepatitisXx_NEWLINE_xXHas known active Hepatitis B or Hepatitis C infection.Xx_NEWLINE_xXActive or chronic infection of hepatitis B virus or hepatitis CXx_NEWLINE_xXRecent (< 1 week ago) clinically significant infection, active tuberculosis or evidence of active hepatitis B, hepatitis C or HIV infectionXx_NEWLINE_xXHistory of chronic hepatitis B infection or positive test results for active or chronic hepatitis B or hepatitis CXx_NEWLINE_xXKnown history of HIV infection or a known history of or is positive for Hepatitis B or Hepatitis CXx_NEWLINE_xXPatients must not have liver disease such a cirrhosis, chronic active hepatitis or chronic persistent hepatitisXx_NEWLINE_xXNo active infection with hepatitis BXx_NEWLINE_xXNo active or chronic infection with hepatitis CXx_NEWLINE_xXHepatitis B + patients may be enrolled at the discretion of the investigatorXx_NEWLINE_xXHas known history of Chronic Hepatitis B or CXx_NEWLINE_xXActive hepatitis B or hepatitis CXx_NEWLINE_xXActive hepatitis B infection as determined by hepatitis B surface antigen.Xx_NEWLINE_xXKnown active hepatitis B or hepatitis C infection.Xx_NEWLINE_xXPatients with known active hepatitis or HIV.Xx_NEWLINE_xXSubject with a known history of active chronic HIV, hepatitis B or hepatitis C infections; negative hepatitis C viral load is allowedXx_NEWLINE_xXActive Hepatitis B or CXx_NEWLINE_xXCurrent infection with HIV, Hepatitis B or Hepatitis C. Patients will have serologic testing performed during screening for HIV and Hepatitis B and C. Any serologic results suggestive of an ongoing viral infection will be further investigated as necessary to clarify the patient's status.Xx_NEWLINE_xXKnown HIV or hepatitis B or C viral infectionXx_NEWLINE_xXA diagnosis of active hepatitis B or CXx_NEWLINE_xXKnown active viral or nonviral hepatitis or cirrhosisXx_NEWLINE_xXPatients with known hepatitis B or hepatitis C infection may be eligible providing they have viral load < 800,000 IU/L within 28 days prior to registrationXx_NEWLINE_xXKnown active hepatitis, type A, B or C; patients who are seropositive because of hepatitis B virus vaccine are eligibleXx_NEWLINE_xXNegative screening tests for hepatitis B and hepatitis C; patients with positive results that do not indicate true active or chronic infection may enroll after discussion and consensus agreement by the treating physician and principal investigatorXx_NEWLINE_xXHepatitis B or C infectionXx_NEWLINE_xXKnown hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection.Xx_NEWLINE_xXKnown active or chronic viral hepatitis or history of any type of hepatitis within the last 6 monthsXx_NEWLINE_xXHas known active Hepatitis B or Hepatitis CXx_NEWLINE_xXKnown infection with hepatitis B, hepatitis C, or HIV.Xx_NEWLINE_xXKnown history of active hepatitis B or hepatitis C infectionXx_NEWLINE_xXActive or latent virus disease (HIV, hepatitis B and hepatitis C)Xx_NEWLINE_xXDiagnosis of infection with HIV or chronic infection with hepatitis B or CXx_NEWLINE_xXActive hepatitis B or hepatitis CXx_NEWLINE_xXActive hepatitis B or hepatitis C infectionXx_NEWLINE_xXKnown infection with hepatitis B, C or HIVXx_NEWLINE_xXHepatitis B or C infectionXx_NEWLINE_xXknown or suspected past hepatitis B infection,Xx_NEWLINE_xXmother known to have hepatitis BXx_NEWLINE_xXKnown disease or history of active or chronic hepatitis C and/or B infectionXx_NEWLINE_xXPatients with liver disease such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitis, or patients with defined elevated ALT/ AST/ Bilirubin.Xx_NEWLINE_xXActive hepatitis B, unless patient has been on antiviral agents for at least 2 months (baseline testing not required)Xx_NEWLINE_xXActive hepatitis B infection, active hepatitis C infection or known HIV carrier.Xx_NEWLINE_xXKnown history of or is positive for Hepatitis B or Hepatitis CXx_NEWLINE_xXKnown HIV or active hepatitis B or C infectionXx_NEWLINE_xXChronic active or acute viral hepatitis A, B, or C infection, or a hepatitis B or C carrierXx_NEWLINE_xXKnown active Hepatitis B or CXx_NEWLINE_xXKnown acute or chronic hepatitis B or hepatitis C infectionXx_NEWLINE_xXKnown hepatitis B surface antigen-positive, or known or suspected active hepatitis C infectionXx_NEWLINE_xXPatients with history of untreated hepatitis B or who are known carriers of hepatitis B will be excluded from this trial; all subjects will be screened prior to study entryXx_NEWLINE_xXNo history of chronic hepatitis B or CXx_NEWLINE_xXA risk of reactivation of hepatitis B or C.Xx_NEWLINE_xXHave achieved a sustained virologic response for 12 weeks after cessation of hepatitis C antiviral treatment (in HIV-positive subjects with hepatitis C)Xx_NEWLINE_xXPatients who have HIV, Hepatitis B or CXx_NEWLINE_xXSubject has active hepatitis B or C or other active hepatic disorder.Xx_NEWLINE_xXKnown clinically active infection with hepatitis B or hepatitis C virusXx_NEWLINE_xXOngoing or active infection, known HIV positive, known to be hepatitis B surface antigen-positive or has known or suspected active hepatitis C infection.Xx_NEWLINE_xXActive or chronic hepatitis C and/or B infectionXx_NEWLINE_xXAny known positive test for hepatitis B or hepatitis C virus indicating acute or chronic infection is not permittedXx_NEWLINE_xXHas active hepatitis B or hepatitis C infection, or co-infection with both hepatitis B and C virusXx_NEWLINE_xXNo active or chronic hepatitis C and/or B infectionXx_NEWLINE_xXKnown active Hepatitis B or CXx_NEWLINE_xXParticipant has known active Hepatitis B, Hepatitis C or tuberculosis. Active Hepatitis B is defined as a known positive HBsAg result. Active Hepatitis C is defined by a known positive Hepatitis C antibody result and known quantitative Hepatitis C virus (HCV) ribonucleic acid (RNA) results greater than the lower limits of detection of the assay.Xx_NEWLINE_xXActive/uncontrolled viral hepatitisXx_NEWLINE_xXActive hepatitis B or C infectionXx_NEWLINE_xXUntreated hepatitis B infectionXx_NEWLINE_xXPatients with known active hepatitis.Xx_NEWLINE_xXKnown active Hepatitis B or CXx_NEWLINE_xXHas known active Hepatitis B (HBV) or Hepatitis C (HCV)Xx_NEWLINE_xXActive hepatopathy of any origin including active hepatitis B and hepatitis CXx_NEWLINE_xXKnown immunodeficiency or HIV, Hepatitis B or Hepatitis C positivity.Xx_NEWLINE_xXHistory of human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); hepatitis C infection is allowed as long as there is no active disease and is cleared by GI consultation; HIV screening is not required for this studyXx_NEWLINE_xXPositive hepatitis B (hepatitis B surface antigen and antibody) and/or hepatitis C (hepatitis C antibody test) as indicated by serologies conducted =< 3 months prior to starting study if liver function tests are outside of the normal institutional range\r\n* NOTE: patients with hepatitis B or C serologies indicating active infection without known active disease must meet the eligibility requirements for ALT, AST, total bilirubin, INR, PTT, and alkaline phosphatase on at least two consecutive occasions, separated by at least 1 weekXx_NEWLINE_xXHas known active Hepatitis B unless subject has been on antiviral agents for at least 2 months (baseline testing not required)Xx_NEWLINE_xXKnown active Hepatitis B or Hepatitis CXx_NEWLINE_xXActive Hepatitis B or hepatitis CXx_NEWLINE_xXKnown history of chronic hepatitis B or CXx_NEWLINE_xXKnown active Hepatitis B or CXx_NEWLINE_xXActive viral hepatitisXx_NEWLINE_xXIndividuals with active hepatitis B or C are ineligibleXx_NEWLINE_xXKnown active Hepatitis B or CXx_NEWLINE_xXIndividuals with active uncontrolled hepatitis B or C are ineligibleXx_NEWLINE_xXActive hepatitis B or hepatitis C with abnormal liver function tests.Xx_NEWLINE_xXActive, uncontrolled infection, including hepatitis B, hepatitis CXx_NEWLINE_xXLiver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitisXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); hepatitis C infection is allowed as long as there is no active disease and is cleared by GI consultationXx_NEWLINE_xXEvidence of active hepatitis B (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody) or active hepatitis C infection; evidence of active human immunodeficiency virus (HIV) infectionXx_NEWLINE_xXActive hepatitis B or hepatitis CXx_NEWLINE_xXHepatitis B or CXx_NEWLINE_xXHistory of hepatitis B or CXx_NEWLINE_xXHepatitis B or CXx_NEWLINE_xXActive hepatitis A, B or CXx_NEWLINE_xXEvidence of active Hepatitis B or C or HIVXx_NEWLINE_xXPatients with active hepatitis B or C, or chronic hepatitis B or C requiring treatment with antiviral therapyXx_NEWLINE_xXAll patients known to be positive for hepatitis B will be excluded from the study, and those at high risk for hepatitis B infection will be screenedXx_NEWLINE_xXKnown seropositivity to human immunodeficiency virus (HIV), current acute or chronic hepatitis B (hepatitis B surface-antigen positive), hepatitis C, cirrhosis or evidence of decompensated liver disease. Patients with resolved Hepatitis B can be included.Xx_NEWLINE_xXSubjects with acute hepatitisXx_NEWLINE_xXKnown history of HIV or hepatitis C or BXx_NEWLINE_xXChronic active or acute viral hepatitis A, B, or C infection, or hepatitis B or C carrierXx_NEWLINE_xXKnown active hepatitis B or C infectionXx_NEWLINE_xXActive hepatitis A or B.Xx_NEWLINE_xXKnown active Hepatitis B or Hepatitis CXx_NEWLINE_xXPatients with a known history of liver disease, autoimmune hepatitis, sclerosing cholangitis, or hepatitis B or C are not eligible for participationXx_NEWLINE_xXPatients with known hepatitis or unstable liver disease, and/or positive serologies for Hepatitis B or C and HIV.Xx_NEWLINE_xXActive hepatitis B or hepatitis CXx_NEWLINE_xXKnown positive patients for infectious hepatitis, type A, B, CXx_NEWLINE_xXHistory of HIV infection or chronic hepatitis B or CXx_NEWLINE_xXNo active hepatitis B or C infectionXx_NEWLINE_xXCOHORT B: No active or chronic infection with HIV, hepatitis B or hepatitis C (negative screening tests required)Xx_NEWLINE_xXPrior, current, or chronic hepatitis B or hepatitis C infectionXx_NEWLINE_xXSubjects with confirmed Hepatitis A, B or CXx_NEWLINE_xXPatients with active hepatitis A, hepatitis B, or hepatitis C infectionXx_NEWLINE_xXParticipants with active hepatitis B, hepatitis C, or tuberculosisXx_NEWLINE_xXKnown carrier of Hepatitis B and / or Hepatitis C (whether active disease or not).Xx_NEWLINE_xXKnown active or chronic viral hepatitis or history of any type of hepatitis within the last 6 months.Xx_NEWLINE_xXAny known active liver disease. For participants who are known carriers of HBV/HCV, active hepatitis B/C infection must be ruled out per local guidelinesXx_NEWLINE_xXActive hepatitis B or hepatitis C with abnormal liver function tests.Xx_NEWLINE_xXSubject has active hepatitis B or C, or other active hepatic disorder.Xx_NEWLINE_xXNo history of chronic hepatitis B or or untreated hepatitis C.Xx_NEWLINE_xXPatients with active hepatitis B or hepatitis C are excludedXx_NEWLINE_xXActive hepatitis B infection, active hepatitis C infectionXx_NEWLINE_xXPatients with known active hepatitis (i.e. hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids.Xx_NEWLINE_xXActive hepatitis B or C infection.Xx_NEWLINE_xXActive hepatitis B or CXx_NEWLINE_xXHas a known history of Hepatitis BXx_NEWLINE_xXActive hepatitis B or C infectionXx_NEWLINE_xXParticipant has known active infection with hepatitis B or hepatitis C virus; hepatitis B and C serology testing is not required, unless active infection is suspectedXx_NEWLINE_xXKnown active hepatitis B or C infectionXx_NEWLINE_xXPatients with a diagnosis of chronic hepatitis B are ineligibleXx_NEWLINE_xXHIV positive or active Hepatitis B, and/or active Hepatitis CXx_NEWLINE_xXActive hepatitis B infection as determined by test for hepatitis B surface antigen.Xx_NEWLINE_xXCurrent active hepatic or biliary disease such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitis (with exception of patients with Gilbert's syndrome and asymptomatic gallstones)Xx_NEWLINE_xXKnown active viral infection\r\n* Note: viral hepatitis testing is required at screening for all patientsXx_NEWLINE_xXActive hepatitis A, B, or C infectionXx_NEWLINE_xXChronic active hepatitis B or C.Xx_NEWLINE_xXActive or symptomatic viral hepatitisXx_NEWLINE_xXHIV positive or active Hepatitis A or BXx_NEWLINE_xXActive hepatitis B or hepatitis C infectionXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); known hepatitis C infection is allowed as long as there is no active disease and is cleared by gastrointestinal (GI) consultationXx_NEWLINE_xXActive hepatitis B or hepatitis C, or laboratory evidence for a chronic infection.Xx_NEWLINE_xXKnown to be Hepatitis B or C positive (except HCC patients)Xx_NEWLINE_xXClinical or laboratory evidence of active hepatitis B or hepatitis C 8. History of HIV infection.Xx_NEWLINE_xXInfection with HIV or hepatitis B or C at screeningXx_NEWLINE_xXHistory of hepatitis B or C infection (subjects with evidence of cleared hepatitis B are permitted).Xx_NEWLINE_xXSevere active viral infection, especially hepatitis B.Xx_NEWLINE_xXPatients must have negative hepatitis C virus (HCV) serology; all patients must be screened for hepatitis B infection before starting treatment; those patients who test positive for hepatitis B should be closely monitored for evidence of active hepatitis B virus (HBV) infection and hepatitis during and for several months after rituximab treatment; PCNSL patients with a history of hepatitis B infection should be treated with entecavir or lamivudine (physician discretion for choice of drug) as antiviral prophylaxis to prevent hepatitis B reactivationXx_NEWLINE_xXPatient has known historical or active infection with HIV, hepatitis B, or hepatitis CXx_NEWLINE_xXNo evidence of chronic active hepatitis or cirrhosisXx_NEWLINE_xXActive hepatitis and/or known HIV carrierXx_NEWLINE_xXKnown active Hepatitis B or Hepatitis C virus infectionXx_NEWLINE_xXPresence of known hepatitis B or hepatitis C infection, regardless of control on antiviral therapyXx_NEWLINE_xXPatients who are known to be HIV positive and/or have active hepatitis B or C infectionXx_NEWLINE_xXKnown active hepatitis, a history of viral hepatitis B or hepatitis CXx_NEWLINE_xXActive liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitisXx_NEWLINE_xXKnown hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infectionXx_NEWLINE_xXActive Hepatitis B infection as determined by test for hepatitis B surface antigen.Xx_NEWLINE_xXPrevious exposure to hepatitis A or B vaccinesXx_NEWLINE_xXCurrent or known history of hepatitisXx_NEWLINE_xXKnown history of chronic hepatitis B or CXx_NEWLINE_xXKnown hepatitis B or hepatitis C infection or liver cirrhosisXx_NEWLINE_xXLiver disease such as chronic cirrhosis, active hepatitis or chronic persistent hepatitisXx_NEWLINE_xXEXPANSION COHORT ONLY: Liver disease such as chronic cirrhosis, active hepatitis or chronic persistent hepatitisXx_NEWLINE_xXNo patients known to be positive for HIV, or active Hepatitis A, B, or C.Xx_NEWLINE_xXKnown HIV or hepatitis A, B, or C positivity---ONLY IF ACTIVEXx_NEWLINE_xXSubject has a chronic or acute hepatitis C infectionXx_NEWLINE_xXSubject has a chronic or acute hepatitis B infectionXx_NEWLINE_xXHas known history of or is positive for hepatitis B or hepatitis CXx_NEWLINE_xXActive hepatitis B or C infectionXx_NEWLINE_xXHas a known history of Hepatitis B or known active Hepatitis C virus infectionXx_NEWLINE_xXHas known active Hepatitis B or Hepatitis C.Xx_NEWLINE_xXActive or chronic hepatitis B or hepatitis C as demonstrated by hepatitis B surface antigen positivity and/or anti- hepatitis C virus positivity, respectively. Patients with clinically active or chronic liver disease, including liver cirrhosis of Child-Pugh class C, are also excluded.Xx_NEWLINE_xXSubjects with known active hepatitis (i.e., Hepatitis B or C) due to risk of transmitting the infection through blood or other body fluidsXx_NEWLINE_xXActive hepatitis B or C infectionXx_NEWLINE_xXPresence of an active acute or chronic infection, including urinary tract infection, human immunodeficiency virus (HIV) or viral hepatitis HIV patients are excluded based on immunosuppression which may render them unable to respond to the vaccine; patients with chronic hepatitis are excluded because of concern that hepatitis could be exacerbated by the injections; if clinically indicate HIV/viral hepatitis testing will be performed to confirm statusXx_NEWLINE_xXActive hepatitis B or C infectionXx_NEWLINE_xXPrior or ongoing liver disease including known cirrhosis, hepatitis B or C infection but not to exclude patients with a distant history of resolved hepatitis A infectionXx_NEWLINE_xXHepatitis C infection; patient may have a hepatitis C infection; however, each patient will require a hepatology consultation; the risk/benefit profile of transplant and hepatitis C will be discussed with the patient and eligibility determined by the principal investigator and lead associate investigatorXx_NEWLINE_xXPatients known to be positive for hepatitis B or to have active hepatitis C infection;Xx_NEWLINE_xXClinically significant active infection (e.g. tuberculosis, viral hepatitis, HIV)Xx_NEWLINE_xXSubjects with known active Hepatitis A, B or C (testing not required).Xx_NEWLINE_xXPatients with acute or chronic hepatitisXx_NEWLINE_xXParticipant with active hepatitis B or CXx_NEWLINE_xXHistory of HIV infection or active hepatitis B (chronic or acute) or hepatitis C infectionXx_NEWLINE_xXKnown acute viral hepatitisXx_NEWLINE_xXActive hepatitis B infection as documented by positive hepatitis B polymerase chain reaction (PCR) assayXx_NEWLINE_xXSubjects with known active hepatitis B or C, or chronic hepatitis B or C requiring treatment with antiviral therapy.Xx_NEWLINE_xXPositive for Hepatitis B, Hepatitis C, or HIVXx_NEWLINE_xXPatients with known active hepatitis C are excludedXx_NEWLINE_xXActive hepatitis A or B.Xx_NEWLINE_xXSubject has active hepatitis B or C or other active hepatic disorder.Xx_NEWLINE_xXKnown active hepatitis A, B or CXx_NEWLINE_xXEvidence of active or prior hepatitis infection.Xx_NEWLINE_xXKnown to be positive for hepatitis B by surface antigen expression; known to have active hepatitis C infection (positive by polymerase chain reaction or on antiviral therapy for hepatitis C within the last 6 months); known to be active cytomegalovirus (CMV) infection or herpes zoster infectionXx_NEWLINE_xXLaboratory or clinical evidence of active infectious hepatitisXx_NEWLINE_xXPatients with active viral hepatitisXx_NEWLINE_xXKnown history of active or chronic hepatitis C and/or B infectionXx_NEWLINE_xXActive evidence of hepatitis B or C infection; hepatitis B surface antigen positiveXx_NEWLINE_xXKnown infection with HIV and active infection with hepatitis B or C.Xx_NEWLINE_xXActive hepatitis B or C infection as defined by seropositivity for hepatitis B (hepatitis B surface antigen [HbsAg]) or hepatitis C (hepatitis C antibody) and elevated liver transaminases (defined as above the ULN per the institution normal ranges)Xx_NEWLINE_xXPrior, current, or chronic hepatitis B or hepatitis C infectionXx_NEWLINE_xXChronic active or acute viral hepatitis A, B, or C infection or hepatitis B or C carrierXx_NEWLINE_xXChronic active or acute viral hepatitis A, B, or C infection (testing required for hepatitis B and C)Xx_NEWLINE_xXActive or chronic viral hepatitis or history of any type of hepatitis within the last 6 monthsXx_NEWLINE_xXKnown acute or chronic hepatitis B or CXx_NEWLINE_xXChronic active or acute viral hepatitis A, B, or C infection (testing required for hepatitis B and C), or hepatitis B or C carrierXx_NEWLINE_xXKnown active or chronic hepatitis B or hepatitis C infectionXx_NEWLINE_xXActive infection including known AIDS or Hepatitis C or with a fever ?38.5°C within 3 days prior to study enrollmentXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); known hepatitis C infection is allowed as long as there is no active disease and is cleared by gastrointestinal (GI) consultationXx_NEWLINE_xXDetectable Hepatitis C virus (indicative of active Hepatitis C)Xx_NEWLINE_xXHave either active or chronic hepatitis B or C requiring treatment with antiviral therapy.Xx_NEWLINE_xXPatients with active hepatitisXx_NEWLINE_xX7. Subjects with known infection with hepatitis A, B or C (testing not required).Xx_NEWLINE_xXKnown infection with HIV or active infection with hepatitis B or hepatitis CXx_NEWLINE_xXChronic active hepatitis B or C infectionXx_NEWLINE_xXKnown immunodeficiency or HIV positivity, active Hepatitis B or active Hepatitis C.Xx_NEWLINE_xXKnown HIV or active hepatitis B or C viral infection.Xx_NEWLINE_xXHas a known history of active hepatitis B or C. Healthy carriers of hepatitis B are not allowed on this studyXx_NEWLINE_xXPatients with hepatitis B and C will be excludedXx_NEWLINE_xXHas known active Hepatitis B or Hepatitis C.Xx_NEWLINE_xXKnown history of hepatitis C and recovery status has not been determined at time of screeningXx_NEWLINE_xXActive hepatitis B or C infectionXx_NEWLINE_xXPatients with hepatitisXx_NEWLINE_xXKnown HIV-positive individuals on combination antiretroviral therapy, patients with known active hepatitis B or C, or chronic hepatitis B or C requiring treatment with antiviral therapyXx_NEWLINE_xXChronic hepatitis with advanced, decompensated hepatic disease or cirrhosis of the liver or history of chronic virus hepatitis or known viral hepatitis carrier (patient recovered from hepatitis A will be allowed to enter the study)Xx_NEWLINE_xXCurrent infection with HIV, Hepatitis B or Hepatitis CXx_NEWLINE_xXChronic active or acute viral hepatitis A, B, or C infection (testing required for hepatitis B and C), or hepatitis B or C carrierXx_NEWLINE_xXSubject carries a diagnosis of active hepatitis B or CXx_NEWLINE_xXKnown infection with HIV, HTLV-I, Hepatitis B, or Hepatitis C.Xx_NEWLINE_xXParticipants with active hepatitis B, active hepatitis C, or active tuberculosisXx_NEWLINE_xXKnown HIV, hepatitis B or hepatitis C.Xx_NEWLINE_xXKnown to be positive for hepatitis B. Known to have active hepatitis C infection or on antiviral therapy for hepatitis C within the last 6 months.Xx_NEWLINE_xXActive hepatitis B or CXx_NEWLINE_xXKnown HIV infection and/or active Hepatitis B or C infectionXx_NEWLINE_xXHistory of or current active infection with hepatitis B, hepatitis C or HIVXx_NEWLINE_xXKnown chronic active Hepatitis B or C, or HIV infectionXx_NEWLINE_xXPatients with chronic active hepatitis or cirrhosis; if positive hepatitis serology, the study chair may deem the patient eligible based on the results of liver biopsyXx_NEWLINE_xXPast medical history of infection with HIV, hepatitis B or hepatitis CXx_NEWLINE_xXActive hepatitis B or C, but participants on stable medications for hepatitis B or C.Xx_NEWLINE_xXChronic hepatitis B or C infection.Xx_NEWLINE_xXPrior, current or chronic hepatitis B or hepatitis C infectionXx_NEWLINE_xXSubject has a known history of acute or chronic hepatitis B (HBV), HIV or hepatitis C (HCV) infection.Xx_NEWLINE_xXChronic or active hepatitis B or C, requiring antiviral therapyXx_NEWLINE_xXPatients known to be seropositive for hepatitis C hepatitis BXx_NEWLINE_xXActive viral hepatitisXx_NEWLINE_xXKnown to be positive for HIV, or to have active hepatitis B, or hepatitis C, or have active infection of any kind requiring systemic therapyXx_NEWLINE_xXKnown hepatitis B surface antigen positive or known or suspected active hepatitis C infection.Xx_NEWLINE_xXActive hepatitis B infection active hepatitis C infection and/or known HIV carrier.Xx_NEWLINE_xXChronic hepatitis B or C infectionXx_NEWLINE_xXHistory of any hepatitis (A,B or C)Xx_NEWLINE_xXKnown to have active hepatitis C infection (positive by polymerase chain reaction or on antiviral therapy for hepatitis C within the last 6 months)Xx_NEWLINE_xXKnown active hepatitis B or CXx_NEWLINE_xXActive Hepatitis B infection in the absence of adequate antiviral therapyXx_NEWLINE_xXCurrent known active infection with HIV, hepatitis B or C virusesXx_NEWLINE_xXEvidence of hepatitis B infectionXx_NEWLINE_xXDONOR: Evidence of hepatitis B infectionXx_NEWLINE_xXSubject has active hepatitis B or C, or other active hepatic disorderXx_NEWLINE_xXInfection with HIV or hepatitis B or C at screeningXx_NEWLINE_xXEvidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serologyXx_NEWLINE_xXChronic or active hepatitis B or C, requiring antiviral therapyXx_NEWLINE_xXKnown HIV, Hepatitis A, B or Hepatitis C infectionXx_NEWLINE_xXActive hepatitis A or B.Xx_NEWLINE_xXKnown history of Hepatitis B or C infection or HIV infectionXx_NEWLINE_xXKnown active Hepatitis B/ Hepatitis C/ HIV infectionXx_NEWLINE_xXKnown hepatitis B surface antigen-positive, or known or suspected active hepatitis C infectionXx_NEWLINE_xXPatients with known hepatitis B or hepatitis C infection may be eligible providing they have viral load < 800,000 IU/mL within 28 days prior to registrationXx_NEWLINE_xXHistory of chronic active hepatitisXx_NEWLINE_xXHistory of any hepatitis (A, B or C)Xx_NEWLINE_xXHistory of grade 3-4 drug-related hepatitisXx_NEWLINE_xXKnown active hepatitis B or C infectionXx_NEWLINE_xXKnown positive for Human Immunovirus (HIV) or infectious Hepatitis type C or active infectious Hepatitis type B.Xx_NEWLINE_xXKnown active hepatitis A, B or CXx_NEWLINE_xXHistory of HIV, hepatitis B, or hepatitis CXx_NEWLINE_xXPatients with current evidence of hepatitis A, B, or C (i.e., active hepatitis)Xx_NEWLINE_xXPatient has known, active hepatic disease (ie, hepatitis B or C).Xx_NEWLINE_xXActive/chronic hepatitis B or CXx_NEWLINE_xXKnown active hepatic disease (known hepatic cirrhosis, hepatitis B surface antigen positive status, or suspected active hepatitis C infection)Xx_NEWLINE_xXKnown active hepatic disease (known hepatic cirrhosis, hepatitis B surface antigen positive status, or suspected active hepatitis C infection)Xx_NEWLINE_xXActive hepatitis B, hepatitis CXx_NEWLINE_xXKnown active hepatitis B, hepatitis CXx_NEWLINE_xXKnown human immunodeficiency (HIV) seropositive, hepatitis C infection, and/or hepatitis B (except for patients with hepatitis B surface antigen [SAg] or core antibody receiving and responding to antiviral therapy directed at hepatitis B: these patients are allowed).Xx_NEWLINE_xXCirrhosis or chronic active/persistent hepatitisXx_NEWLINE_xXKnown acute or chronic hepatitis B or hepatitis C infection as determined by serologic testsXx_NEWLINE_xXInfection with HIV or hepatitis B or C at screeningXx_NEWLINE_xXKnown significant chronic liver disease, such as cirrhosis or active hepatitis (potential participants who test positive for hepatitis B surface antigen or hepatitis C antibodies are allowed provided they do not have active disease requiring antiviral therapy)Xx_NEWLINE_xXPatient has known or suspected HIV, positive for hepatitis B or is known or suspected to have active hepatitis C infection.Xx_NEWLINE_xXActive hepatitis B or C viral infectionXx_NEWLINE_xXHepatitis B or C.Xx_NEWLINE_xXActive infection including HIV, hepatitis A, B or CXx_NEWLINE_xXKnown acute or chronic hepatitis B or hepatitis C infection as determined by serologic testsXx_NEWLINE_xXParticipants who are known to have active hepatitis A, B, or C viral infection may not participate in this study; active disease is defined as participants with a known viral hepatitis whose liver function tests are elevated beyond the criteria indicatedXx_NEWLINE_xXPositive for hepatitis BsAg or HIV Ab or hepatitis CXx_NEWLINE_xXActive hepatitis B or C infectionXx_NEWLINE_xXNo liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis.Xx_NEWLINE_xXEvidence of acute or chronic active hepatitis or cirrhosisXx_NEWLINE_xXHepatitis C infection; patient may have hepatitis C infection; however, each patient will require a hepatology consultation; the risk/benefit profile of transplant and hepatitis C will be discussed with the patient and eligibility determined by the principal investigator and protocol chairpersonXx_NEWLINE_xXLiver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitisXx_NEWLINE_xXActive hepatitis B or hepatitis C infection (hepatitis B surface antigen testing required)Xx_NEWLINE_xXKnown or active HIV, viral hepatitis B or CXx_NEWLINE_xXChronic active hepatitis or cirrhosisXx_NEWLINE_xXknown HIV or HepatitisXx_NEWLINE_xXActive uncontrolled infection, including Hepatitis B, Hepatitis C infection. Patients with anti-HBc positive, or HBsAg but DNA negative are exception(s)Xx_NEWLINE_xXNo currently active hepatitis B or CXx_NEWLINE_xXEvidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serologyXx_NEWLINE_xXActive hepatitis B or C infectionXx_NEWLINE_xXChronic, active, or acute viral hepatitis A, B, or C infection, or a hepatitis B or C carrierXx_NEWLINE_xXNo evidence of chronic active hepatitis or cirrhosisXx_NEWLINE_xXActive chronic hepatitis C and/or B infectionXx_NEWLINE_xXKnown HIV positive, hepatitis B surface antigen positive or known or suspected active hepatitis C infection.Xx_NEWLINE_xXHas known active Hepatitis B or CXx_NEWLINE_xXChronic hepatitis B or C infection (e.g. hepatitis B surface antigen [Ag] positive or detectable viral load for hepatitis B or C); patients with prior evidence of hepatitis B or C without active infection are eligibleXx_NEWLINE_xXKnown hepatitis B surface antigen positive, or known or suspected active hepatitis C infection.Xx_NEWLINE_xXKnown positive hepatitis with evidence of active diseaseXx_NEWLINE_xXKnown history of HIV or active hepatitis B/C (patients who have been vaccinated for hepatitis B and do not have a history of infection are eligible)Xx_NEWLINE_xXDONOR: Evidence of active infection or viral hepatitisXx_NEWLINE_xXPatients with a history of chronic active hepatitis, cirrhosis or hepatic encephalopathyXx_NEWLINE_xXActive hepatitis B (chronic or acute), or hepatitis C (exception for participants in Arm A and Arm F)Xx_NEWLINE_xXKnown active clinically relevant liver disease (eg, active hepatitis B, or active hepatitis C);Xx_NEWLINE_xXPatients must be on antiviral therapy per the local standard of care if active or occult hepatitis B (hepatitis B virus [HBV]) infection; patients with active hepatitis C (hepatitis C virus [HCV]) may not be antiviral therapyXx_NEWLINE_xXSerious concurrent illness or clinically relevant active infection, including known diagnosis of HIV and hepatitis B or C, as defined in the protocolXx_NEWLINE_xXActive or uncontrolled clinically serious infection. (Participants with chronic viral hepatitis are eligible.)Xx_NEWLINE_xXActive hepatitis B or hepatitis CXx_NEWLINE_xXParticipants with active hepatitis B, active hepatitis C, or active tuberculosisXx_NEWLINE_xXKnown active hepatitis B or CXx_NEWLINE_xXPatients with known history of autoimmune hepatitis, hepatitis C or those with hemoglobinopathies (e.g., thalassemia major, sickle cell anemia)Xx_NEWLINE_xXPatients with documented active hepatitis B or C infectionXx_NEWLINE_xXHistory of hepatitis A, B and CXx_NEWLINE_xXKnown positive for infectious hepatitis type C or active infectious hepatitis type BXx_NEWLINE_xXKnown history of HIV or active hepatitis B/C )Xx_NEWLINE_xXFOR THE 31 SUBJECTS ENROLLED IN YEAR 1: History of known active infection with HIV, hepatitis B or hepatitis CXx_NEWLINE_xXOther known causes of significant liver disease including chronic or acute hepatitis B, acute hepatitis A, hemochromatosis, or homozygote alpha-1 antitrypsin deficiencyXx_NEWLINE_xXEvidence of any active uncontrolled infection (bacterial, viral or fungal) or evidence of natural exposure to hepatitis B, hepatitis C or human immunodeficiency virus (HIV); evidence of hepatitis B exposure includes the presence of hepatitis B surface antigenemia, a positive serological test for hepatitis B core antibody or nucleic acid testing (NAT testing) that is positive for hepatitis B; vaccination to hepatitis B is not an exclusion criteria; testing done in the pre-transplant setting is sufficient to rule out infectionXx_NEWLINE_xXPatients with a known confirmed diagnosis of HIV infection or active viral hepatitis.Xx_NEWLINE_xXKnown hepatitis B or CXx_NEWLINE_xXKnown HIV or active hepatitis B or C infectionXx_NEWLINE_xXCurrent infection with HIV, Hepatitis B or Hepatitis CXx_NEWLINE_xXPatient is known to be hepatitis B or hepatitis C-positive (these tests are not required)Xx_NEWLINE_xXPatients with known active hepatitis B or CXx_NEWLINE_xXActive hepatitis B or active hepatitis C infectionXx_NEWLINE_xXPatient with active hepatitis B or CXx_NEWLINE_xXKnown history of HIV or Hepatitis CXx_NEWLINE_xXHepatitis B or hepatitis C active infectionXx_NEWLINE_xXKnown active or chronic hepatitis B or C infection or HIVXx_NEWLINE_xXHas a known history of Hepatitis B or known active Hepatitis C virus infection.Xx_NEWLINE_xXKnown history of hepatitis B or hepatitis C infection or known positive test for hepatitis B surface antigen, hepatitis B core antigen, or hepatitis C polymerase chain reaction.Xx_NEWLINE_xXKnown HIV or active hepatitis B or C viral infectionXx_NEWLINE_xXSubject has active hepatitis B or C.Xx_NEWLINE_xXKnown active or chronic hepatitis B or hepatitis C infectionXx_NEWLINE_xXHistory of any hepatitisXx_NEWLINE_xXKnown chronic active hepatitis or cirrhosisXx_NEWLINE_xXAny positive tests for Hepatitis B or Hepatitis C virus indicating acute or chronic infectionXx_NEWLINE_xXThe patient has known active hepatitis B or C. The determination of active hepatitis B or C is left to the investigator.Xx_NEWLINE_xXPatients with hepatitis B and hepatitis C must be under the care of viral hepatitis expert consultant; patients with hepatitis B are required to be treated with anti-hepatitis B virus (HBV) treatment (e.g., entecavir); patients with hepatitis C need to have received prior and/or ongoing hepatitis C treatmentXx_NEWLINE_xXAbsence of known HIV infection, chronic hepatitis B, or hepatitis C infection; absence of any other serious medical condition which could interfere with oral medication intakeXx_NEWLINE_xXKnown hepatitis B surface antigen-positive or known or suspected active hepatitis C infection (testing not required).Xx_NEWLINE_xXHas known active hepatitis B or hepatitis C.Xx_NEWLINE_xXActive hepatitis B or hepatitis CXx_NEWLINE_xXHas active hepatitis B (HBV) or hepatitis C (HCV).Xx_NEWLINE_xXKnown active viral or nonviral hepatitisXx_NEWLINE_xX